Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis - PubMed
7 hours ago
- #Neoadjuvant Therapy
- #Head and Neck Cancer
- #Immunotherapy
- Neoadjuvant chemoimmunotherapy shows high pathologic response rates in head and neck squamous cell carcinoma (HNSCC).
- Meta-analysis includes 751 patients across 23 studies, comparing chemoimmunotherapy, dual-agent, and single-agent immunotherapy.
- Pooled major and complete pathologic response rates were 66% for chemoimmunotherapy, 18% for dual-agent, and 6% for single-agent immunotherapy.
- 1-year overall survival rates were high across all groups, ranging from 88% to 100%.
- Grade 3-5 adverse events were more common in chemoimmunotherapy (29%) compared to dual-agent (3%) and single-agent (17%) immunotherapy.
- Findings suggest chemoimmunotherapy is superior to immunotherapy alone, warranting phase 3 trials for direct comparison.